New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04197713
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific genetic changes. The goal was to find the best dose and check for side effects, while seeing if the combination could shrink or stabilize tumors. The approach aims to block cancer cell growth and DNA repair, potentially offering a new option for patients who have run out of standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.